OUR JOURNEY
At Smartlens, we are transforming anterior segment disease management through breakthrough technologies that enable remote monitoring and care. Our flagship product, miLens, is the world's smallest wearable microfluidic device for diurnal IOP monitoring - the primary risk factor for glaucoma, the leading cause of irreversible blindness. This non-invasive solution has earned strong market validation, with overwhelming adoption intent from eyecare practitioners across the U.S.
OUR MISSION
Redefining the Way
We Monitor, Diagnose, and Treat Glaucoma and Other Eye Conditions
With a vision to transform anterior segment care, we're expanding beyond miLens to introduce Slit IQ, our AI-powered platform for remote eye exams. Backed by extensive intellectual property, including more than 40 global patents and an exclusive Stanford license, we're building the first comprehensive solution that integrates monitoring, diagnosis, and treatment. Our platform combines advanced microfluidic technology with AI-enhanced diagnostics to make specialist-level eye care more accessible and data-driven than ever.
